| Original language | English |
|---|---|
| Pages (from-to) | 176-177 |
| Number of pages | 2 |
| Journal | The Lancet Diabetes and Endocrinology |
| Volume | 8 |
| Issue number | 3 |
| Early online date | 29 Jan 2020 |
| DOIs | |
| Publication status | Published - 1 Mar 2020 |
Funding
AHB reports personal fees from MSD, Novo Nordisk, Napp, Janssen, Eli Lilly, and Boehringer Ingelheim. SB reports grants from Novo Nordisk; personal fees from MSD, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Napp, Takeda, and Sanofi-aventis; and non-financial support from Napp. AAT reports grants, personal fees and non-financial support from Sanofi and Novo Nordisk; non-financial support from MSD; personal fees and non-financial support from Boehringer Ingelheim; personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen; non-financial support and a travel grant to attend a conference from ResMed; non-financial support from Philips Respironics, Impeto medical, ANSAR, and Aptiva; and grants and non-financial support from Napp.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diabetes Mellitus
- Glucose
- Humans
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver